SCHEMBL26647261

SCHEMBL26647261

CCOc1cc(S(C)(=O)=O)ncc1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ TLR8 Q9NR97 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16234977 0.83 PKM (0.43) HSD17B10ALDH1A1POLBL3MBTL1CA1
SCHEMBL16909250 0.77 NOS3 (0.39) POLBCA12CA1CA2CA9
SCHEMBL28874061 0.76 PIK3CB (0.39) POLBL3MBTL1CA12CA1CA2
SCHEMBL22235444 0.74 HSD17B10 (0.52) MAPTHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL26646908 0.73 TLR8 (0.41) MAPTHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL3257964 0.73 UHRF1 (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL26646826 0.72 HSD17B10 (0.48) MAPTHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL26647136 0.71 ALDH1A1 (0.58) MAPTHSD17B10ALDH1A1KDM4EMEN1
Sulfuric Acid SCHEMBL8642497 0.71 HSD17B10 (0.53) MAPTHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL7028420 0.69 MAPT (0.64) MAPTHSD17B10ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 — — EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
WO-2022240876-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2022-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 MAPT 1102/4885HSD17B10 1265/4885ALDH1A1 2211/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 MAPT 1102/4885HSD17B10 1265/4885ALDH1A1 2211/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 MAPT 1102/4885HSD17B10 1265/4885ALDH1A1 2211/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 MAPT 1102/4885HSD17B10 1265/4885ALDH1A1 2211/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 MAPT 1151/4885HSD17B10 1191/4885ALDH1A1 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback